Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for TMS Synaptic Plasticity Enhancement
NCT04369547Phase 1Withdrawn
- Sponsor
- University of Calgary
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Roflumilast Sequence with Placebo Sequence (2 arms). Primary endpoint: TMS Evoked Potential amplitude. Planned start Jan 2022; status: withdrawn.
02
Drugs
roflumilast
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04369547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369547.